SCHEMBL16013103

SCHEMBL16013103

C=C(C)c1c(OC)cc(C(=O)OC)cc1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.49
KDM4E B2RXH2 4/20 0.47
ALDH1A1 P00352 1/20 0.47
CA1 P00915 3/20 0.47
CA2 P00918 3/20 0.47
CA12 O43570 2/20 0.47
CA7 P43166 2/20 0.47
CA9 Q16790 2/20 0.47
CA14 Q9ULX7 2/20 0.47
CNR2 P34972 1/20 0.46
LMNA P02545 3/20 0.46
POLB P06746 2/20 0.46
GAA P10253 1/20 0.46
NFKB1 P19838 1/20 0.46
XDH P47989 1/20 0.46
GFER P55789 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46
FUT7 Q11130 1/20 0.46
TDP1 Q9NUW8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31484816 0.82 EGFR (0.44) MAPTKDM4EALDH1A1CA1CA2
SCHEMBL11855071 0.79 MAPT (0.54) MAPTKDM4EALDH1A1CA1CA2
SCHEMBL732865 0.78 KDM4E (0.49) MAPTKDM4EALDH1A1CA1CA2
SCHEMBL31238916 0.78 CNR2 (0.62) MAPTKDM4EALDH1A1CA1CA2
SCHEMBL13979824 0.78 MAPT (0.49) MAPTKDM4EALDH1A1CA1CA2
SCHEMBL11519523 0.78 CYP3A4 (0.50) MAPTKDM4EALDH1A1CA1CA2
SCHEMBL3783006 0.78 KDM4E (0.49) MAPTKDM4EALDH1A1CA1CA2
SCHEMBL30842508 0.77 MAPT (0.57) MAPTKDM4EALDH1A1CA1CA2
SCHEMBL30959745 0.77 MAPT (0.57) MAPTKDM4EALDH1A1CA1CA2
SCHEMBL2900038 0.76 KDM4E (0.51) MAPTKDM4EALDH1A1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136556-A1 NOVEL MODULATORS OF THE ARYL HYDROCARBON RECEPTOR AND METHODS OF USE THEREOF ALLIANTHERA BOSTON INC. 2025-05-01 US disclosed
EP-4430028-A2 NOVEL MODULATORS OF THE ARYL HYDROCARBON RECEPTOR AND METHODS OF USE THEREOF Allianthera (Suzhou) Biopharmaceutical Co., Ltd. (CN) 2024-09-18 EP disclosed
WO-2023086428-A2 NOVEL MODULATORS OF THE ARYL HYDROCARBON RECEPTOR AND METHODS OF USE THEREOF ALLIANTHERA (SUZHOU) BIOPHARMACEUTICAL CO., LTD. (CN) 2023-05-19 WO disclosed
WO-2023086428-A2 NOVEL MODULATORS OF THE ARYL HYDROCARBON RECEPTOR AND METHODS OF USE THEREOF ALLIANTHERA (SUZHOU) BIOPHARMACEUTICAL CO., LTD. (CN) 2023-05-19 WO disclosed
US-20220298163-A1 BTK INHIBITORS WITH IMPROVED DUAL SELECTIVITY BEIGENE, LTD. (KY) 2022-09-22 US disclosed
US-11377449-B2 BTK inhibitors with improved dual selectivity BEIGENE, LTD. (KY) 2022-07-05 US disclosed
US-11377449-B2 BTK inhibitors with improved dual selectivity BEIGENE, LTD. (KY) 2022-07-05 US disclosed
EP-3608308-B1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS AG (CH) 2021-07-21 EP disclosed
EP-3608308-B1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS AG (CH) 2021-07-21 EP disclosed
CN-107879960-B Lipids and lipid compositions for delivery of active ingredients 诺华股份有限公司 2021-06-22 CN disclosed
EP-2964608-B1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS AG (CH) 2019-08-28 EP disclosed
WO-2019034009-A1 Btk INHIBITORS WITH IMPROVED DUAL SELECTIVITY BEIGENE, LTD. (KY) 2019-02-21 WO disclosed
US-20180369386-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. 2018-12-27 US disclosed
US-10124065-B2 Lipids and lipid compositions for the delivery of active agents NOVARTIS AG (CH) 2018-11-13 US disclosed
US-20160106842-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. 2016-04-21 US disclosed
US-20160106842-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. 2016-04-21 US disclosed
US-20160106842-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. 2016-04-21 US disclosed
EP-2964608-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS Novartis AG (CH) 2016-01-13 EP disclosed
WO-2014136086-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS AG (CH) 2014-09-12 WO disclosed
WO-2014136086-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS AG (CH) 2014-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220298163-A1 BTK INHIBITORS WITH IMPROVED DUAL SELECTIVITY BTK, SYK, LYN MAPT 2026/4885KDM4E 711/4885ALDH1A1 4795/4885
US-20250136556-A1 NOVEL MODULATORS OF THE ARYL HYDROCARBON RECEPTOR AND METHODS OF USE THEREOF AHR, ARNT, NR1H2 MAPT 4822/4885KDM4E 2858/4885ALDH1A1 469/4885
US-11377449-B2 BTK inhibitors with improved dual selectivity BTK, SYK, LYN MAPT 2026/4885KDM4E 711/4885ALDH1A1 4795/4885
US-10124065-B2 Lipids and lipid compositions for the delivery of active agents LIPA, LPAR1, LPAR4 MAPT 4044/4885KDM4E 2406/4885ALDH1A1 2488/4885
US-20180369386-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS LIPA, LPAR1, LPAR4 MAPT 4044/4885KDM4E 2406/4885ALDH1A1 2488/4885
US-20160106842-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS LIPA, LPAR1, LPAR4 MAPT 4044/4885KDM4E 2406/4885ALDH1A1 2488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.